Marekani - Kiingereza - NLM (National Library of Medicine)

msn laboratories private limited - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. toremifene citrate is contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.6).] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, toremifene citrate can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using toremifene citrate. if this drug is used during pregnancy, or if the patient becomes pregnant whi

Marekani - Kiingereza - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. toremifene citrate is contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.6).] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, toremifene citrate can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using toremifene citrate. if this drug is used during pregnancy, or if the patient becomes pregnant whi

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - remifentanil hydrochloride -

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - remifentanyl hydrochloride - powder for solution for injection - 1mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - remifentanyl hydrochloride - powder for solution for injection - 2mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - remifentanyl hydrochloride - powder for solution for injection - 5mg

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - remifentanil hydrochloride - pdr/conc/soln/inj/inf - 5 milligram

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - remifentanil hydrochloride - pdr/conc/soln/inj/inf - 2 milligram

Marekani - Kiingereza - NLM (National Library of Medicine)

kyowa kirin, inc. - toremifene citrate (unii: 2498y783qt) (toremifene - unii:7nfe54o27t) - toremifene 60 mg - fareston® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. fareston is contraindicated in patients with known hypersensitivity to the drug. toremifene should not be prescribed to patients with congenital/acquired qt prolongation (long qt syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia. pregnancy category d [see warnings and precautions (5.7).] based on its mechanism of action in humans and findings of increased pregnancy loss and fetal malformation in animal studies, fareston can cause fetal harm when administered to a pregnant woman. toremifene caused embryo-fetal toxicities at maternal doses that were lower than the 60 mg daily recommended human dose on a mg/m2 basis. there are no adequate and well-controlled studies in pregnant women using fareston. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be appris

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

hospira uk limited - remifentanil hydrochloride - pdr/conc/soln/inj/inf - 1 milligram - opioid anesthetics